Biotage (BIOT.ST) Stock Price
Biotage Price
Revenue has compounded at 8.6% per year over the past 19 years to 2.06 B SEK. Earnings per share have grown at 23.2% per year over the last 15 years. Biotage's net margin stands at 13.8%, down from 16.0% several years earlier. The payout ratio is around 45% of earnings. The dividend has grown at 14.9% per year over the past 15 years.
Biotage stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Biotage over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biotage stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biotage's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Biotage Price |
|---|
Biotage Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotage Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB SEK |
| EBITM SEK |
| EBIT MARGIN% |
| NET INCOMEM SEK |
| NET INCOME GROWTH% |
| DIVIDENDDIV.SEK |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2031e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.49 | 0.61 | 0.67 | 0.75 | 0.91 | 1.10 | 1.09 | 1.23 | 1.57 | 1.86 | 2.06 | 1.91 | 2.07 | 2.26 | 3.53 | 4.79 |
| 10.36 | 24.49 | 9.34 | 12.14 | 21.66 | 20.99 | -0.82 | 12.82 | 27.11 | 18.90 | 10.42 | -7.00 | 8.16 | 9.09 | 56.56 | 35.48 |
| 54.29 | 56.07 | 57.72 | 60.96 | 61.10 | 62.22 | 60.99 | 61.28 | 60.54 | 54.40 | 62.69 | 62.69 | 62.69 | 62.69 | 62.69 | 62.69 |
| 0.27 | 0.34 | 0.39 | 0.46 | 0.56 | 0.69 | 0.67 | 0.76 | 0.95 | 1.01 | 1.29 | 1.20 | 1.30 | 1.41 | 2.21 | 3.00 |
| 49.00 | 74.00 | 99.00 | 133.00 | 173.00 | 210.00 | 209.00 | 271.00 | 330.00 | 376.00 | 383.00 | 383.00 | 414.00 | 452.00 | 708.00 | – |
| 10.00 | 12.13 | 14.84 | 17.78 | 19.01 | 19.07 | 19.14 | 22.00 | 21.07 | 20.19 | 18.63 | 20.03 | 20.02 | 20.04 | 20.05 | – |
| 51.00 | 73.00 | 92.00 | 138.00 | 167.00 | 186.00 | 175.00 | 205.00 | 268.00 | 246.00 | 284.00 | 270.00 | 340.00 | 387.00 | 600.00 | – |
| 24.39 | 43.14 | 26.03 | 50.00 | 21.01 | 11.38 | -5.91 | 17.14 | 30.73 | -8.21 | 15.45 | -4.93 | 25.93 | 13.82 | 55.04 | – |
| 0.60 | 0.75 | 1.00 | 1.25 | 1.40 | 1.50 | – | 1.50 | 1.55 | 1.60 | 1.60 | 1.65 | 1.68 | 1.71 | – | – |
| 20.00 | 25.00 | 33.33 | 25.00 | 12.00 | 7.14 | – | – | 3.33 | 3.23 | – | 3.12 | 1.82 | 1.79 | – | – |
| 64.71 | 64.71 | 64.71 | 64.71 | 65.12 | 65.20 | 65.20 | 66.18 | 66.20 | 80.09 | 80.17 | 80.17 | 80.17 | 80.17 | 80.17 | 80.17 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Biotage generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biotage retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biotage's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Biotage has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biotage's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Biotage stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotage Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotage business model & stock analysis
Biotage SWOT Analysis
Strengths
Biotage AB has several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong research and development team, enabling them to consistently innovate and develop high-quality products. Secondly, Biotage AB has a wide range of product offerings, catering to various industries such as pharmaceuticals, biotechnology, and forensic sciences. This diversification mitigates risk and allows the company to target multiple markets. Thirdly, the company has a well-established global presence, with a strong distribution network in key regions, ensuring efficient delivery of products to customers.
Weaknesses
Despite its strengths, Biotage AB also faces a few weaknesses that need to be addressed. Firstly, the company heavily relies on key suppliers for raw materials, making them vulnerable to supply chain disruptions or price fluctuations. Secondly, Biotage AB faces intense competition from both established players and emerging companies in the industry. To maintain their market share, the company needs to continuously invest in research and development, marketing, and sales efforts. Lastly, Biotage AB lacks brand recognition compared to some of its competitors, which may affect its ability to attract new customers and expand into new markets.
Opportunities
There are several opportunities that Biotage AB can capitalize on to enhance its growth prospects. Firstly, the increasing demand for organic and natural products presents an opportunity for the company to expand its portfolio and cater to the growing customer preferences. Secondly, the advancements in technology, such as automation and robotics, provide avenues for Biotage AB to streamline its manufacturing processes and improve efficiency. Additionally, the company can explore partnerships or acquisitions to enter new markets or gain access to complementary technologies, fueling further growth.
Threats
Biotage AB faces certain threats that could impact its business operations. Firstly, strict regulations and compliance requirements in the industries they serve can pose challenges and increase costs for the company. Adapting to evolving regulations will be crucial to remain competitive. Secondly, economic downturns or uncertainties in global markets can impact customer spending and reduce demand for Biotage AB's products. To mitigate this risk, the company should focus on diversifying its customer base across geographies and industries. Lastly, counterfeit products and intellectual property infringements pose a threat to Biotage AB's brand reputation and profitability, necessitating stringent measures to protect their technology and patents.
Biotage Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Biotage historical P/E ratio, EBIT multiple, and P/S ratio
Biotage annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Biotage shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotage Dividend History
16 years of dividend payments
Biotage dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotage dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Biotage Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/25/2024 | 0.79SEK | 529.79 MSEK | 2024 Q1 |
| 2/15/2024 | 1.15SEK | 585.07 MSEK | 2023 Q4 |
| 7/17/2023 | 1.05SEK | 449.85 MSEK | 2023 Q2 |
| 4/26/2023 | 1.14SEK | 451.67 MSEK | 2023 Q1 |
| 2/15/2023 | 1.46SEK | 437.52 MSEK | 2022 Q4 |
| 11/2/2022 | 1.08SEK | 409.50 MSEK | 2022 Q3 |
| 7/19/2022 | 0.86SEK | 362.71 MSEK | 2022 Q2 |
| 4/28/2022 | 0.87SEK | 353.69 MSEK | 2022 Q1 |
| 2/11/2022 | 0.88SEK | 344.02 MSEK | 2021 Q4 |
| 11/5/2019 | 0.81SEK | 267.96 MSEK | 2019 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Biotage stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Biotage shareholder structure
| % | Name |
|---|---|
4.84505% | |
4.79347% | |
1.14774% | |
0.62422% | |
0.54302% | |
0.52030% |
Biotage Beneficial Ownership Filings (SEC 13D/G)
Biotage Executives and Management Board
Mr. Torben Joergensen
(73)Director · since 2006
Mr. Frederic Vanderhaegen
(58)Chief Executive Officer
Mr. Kieran Murphy
(62)Independent Chairman of the Board
Mr. Peter von Ehrenheim
(70)Independent Director
Ms. Asa Hedin
(63)Independent Director
Biotage Supply Chain
Biotage Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.64 | 0.74 | 0.81 | 0.85 | 0.92 | ||
| 2 | 0.49 | 0.51 | 0.55 | 0.68 | 0.79 | ||
| 3 | 0.13 | 0.67 | 0.77 | 0.65 | 0.56 |
Frequently asked questions about Biotage
Biotage AB operates under a business model focused on providing innovative separation solutions for pharmaceutical, biotech, and academic research organizations. The company specializes in the development, manufacturing, and distribution of instruments, consumables, and software for analytical chemistry, medicinal chemistry, and process development. Biotage's products enable efficient sample preparation, purification, and analysis, leading to improved productivity and quality in various applications. With a strong emphasis on customer-driven solutions, Biotage aims to support researchers and industry professionals in their quest for reliable and efficient chemical analysis and purification techniques. Biotage AB remains dedicated to advancing science and delivering superior products to meet the evolving needs of the life sciences industry.
Biotage stock
Biotage Peer Group
Biotage Ticker
Biotage FIGI
All fundamentals and in-depth analysis of Biotage
Our stock analysis for Biotage stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotage. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.